Trial Profile

Phase I Study of RO5541077 in Patients with B cell Non-Hodgkin s Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Polatuzumab vedotin (Primary)
Indications Non-Hodgkin's lymphoma
Focus Adverse reactions; Pharmacokinetics
Sponsors Chugai Pharmaceutical

Most Recent Events

01 Jan 2021 Results assessing safety, pharmacokinetics and preliminary antitumor activity of Polatuzumab-vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma published in the Japanese Journal of Clinical Oncology
16 Mar 2019 Results ethnic sensitivity assessment by using data from two phase I and a phase II studies presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
13 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com